CAJ | 학술논문

目的：探讨布地奈德联合参麦注射剂对慢性肺源性心脏病急性加重期（AECCP）合并心衰患者心肺功能的影响。方法：将AECCP合并心衰患者80例按数字随机法分为观察组和对照组各40例。对照组在常规治疗的基础上采用参麦注射剂40 ml静脉滴注治疗，观察组在此基础上采用雾化泵吸入布地奈德混悬液1 mg，2次/d，共7 d。比较两组治疗前后的心肺功能指标及不良反应发生情况。结果：与T0比较，两组T2、T3和T4的血浆BNP水平均降低， LVEF、FEV1、FVC和6MWT升高，但观察组T2、T3和T4的血浆BNP水平显著低于对照组，LVEF、肺功能指标及6MWT显著高于对照组（P＜0.05）。两组不良反应发生率比较差异无统计学意义（P＞0.05）。结论：布地奈德联合参麦注射剂治疗AECCP合并心衰可有效改善其心肺功能且不良反应发生少，具有良好的可行性和安全性。
목적：탐토포지내덕연합삼맥주사제대만성폐원성심장병급성가중기（AECCP）합병심쇠환자심폐공능적영향。방법：장AECCP합병심쇠환자80례안수자수궤법분위관찰조화대조조각40례。대조조재상규치료적기출상채용삼맥주사제40 ml정맥적주치료，관찰조재차기출상채용무화빙흡입포지내덕혼현액1 mg，2차/d，공7 d。비교량조치료전후적심폐공능지표급불량반응발생정황。결과：여T0비교，량조T2、T3화T4적혈장BNP수평균강저， LVEF、FEV1、FVC화6MWT승고，단관찰조T2、T3화T4적혈장BNP수평현저저우대조조，LVEF、폐공능지표급6MWT현저고우대조조（P＜0.05）。량조불량반응발생솔비교차이무통계학의의（P＞0.05）。결론：포지내덕연합삼맥주사제치료AECCP합병심쇠가유효개선기심폐공능차불량반응발생소，구유량호적가행성화안전성。
Objective: To investigate the effect of budesonide combined with Shenmai injection on the heart and lung function of patients with acute exacerbations of chronic cor pulmonale (AECCP) complicated with heart failure.Methods: Eighty cases of patients with AECCP and heart failure (HR)were divided into an observation group and a control group with 40 cases each by digital random method. Forty milliliter of Shenmai injection was given by intravenous drip on the basis of conventional treatment in the control group while 1 mg pump inhaled budesonide suspension liquid was given in the observation twice a day for 7 days besides the therapy in the control group. The cardiopulmonary function indexes and adverse reactions were compared between two groups before and after treatment.Results:Compared with T0, plasma BNP levels of T2, T3and T4were reduced while LVEF, FEV1, FVC and 6MWT were increased in two groups, however.the plasma BNP levels were signiifcantly lower while the LVEF, indexes of lung function and 6MWT were signiifcantly higher in the observation group than in the control group (P<0.05). The incidence of adverse reactions in two groups had no statistical significant differences (P>0.05).Conclusion:Budesonide combined with Shenmai injection for the treatment of patients with AECCP and HF can effectively improve cardiopulmonary function with few adverse reactions and thus has good feasibility and safety.